Jun 2026 (Q2 FY26) — Aug 6, 2026
Privia Health Q2 FY26 — Strong Growth and Raised Full-Year Outlook
Read the full callPrivia Health (PRVA) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Privia Health earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 633 | +21.4% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 1.9 | +1.2 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 9.0 | +236.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$22.62 +4.38% · +$0.95
Performance −8.8% 1Y
1Y: $24.81 on 14 Oct 2025 → $22.62. High $28.1 (15 Jul 2026), low $19.1 (23 Sept 2026).
- Previous close
- $21.67
- 52-week range
- $19.1 – $28.1
- One year
- −10.38%
Overview
- Symbol
- PRVA
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Privia Health earnings calls (PRVA)
Financials
What the filings say
Net profit, year on year: +237% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 438 | 461 | 480 | 521 | 580 | 541 | 604 | 633 |
| Operating profit | 6 | 5 | 5 | 3 | 14 | 11 | 7 | 12 |
| Operating margin | 1.3% | 1.1% | 1.1% | 0.6% | 2.5% | 2.1% | 1.2% | 1.9% |
| Other income | 2 | 3 | 3 | 2 | 2 | 2 | 2 | — |
| Profit before tax | 8 | 8 | 8 | 6 | 17 | 13 | 9 | 17 |
| Tax rate | 50.1% | 33.1% | 25.8% | 42.8% | 41.2% | 20.8% | 60.1% | 41.9% |
| Net profit | 4 | 4 | 4 | 3 | 7 | 9 | 3 | 9 |
| EPS ($ per share) | 0.03 | — | 0.03 | 0.02 | 0.06 | — | 0.02 | 0.07 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Equity capital | — | 1 | 1 | 1 | 1 | 1 | 1 |
| Reserves | — | -20 | -208 | -217 | -194 | -179 | -156 |
| Total liabilities | — | 185 | 236 | 274 | 393 | 452 | 578 |
| Fixed assets | — | 5 | 5 | 3 | 2 | 1 | 1 |
| Total assets | — | 329 | 686 | 793 | 1,000 | 1,136 | 1,369 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Cash from operations | 24 | 39 | 55 | 47 | 81 | 109 | 163 |
| Cash from investing | -6 | -0 | -33 | -0 | -43 | -12 | -182 |
| Cash from financing | -11 | -1 | 214 | -20 | 4 | 4 | 7 |
| Net cash flow | 8 | 38 | 236 | 27 | 42 | 102 | -11 |
| Capital expenditure | -6 | -0 | -1 | -0 | -0 | — | — |
| Free cash flow | 19 | 39 | 55 | 47 | 81 | — | — |
Insider filings
71 filings between Dec 12, 2025 and Sep 1, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$22.24M
40 sales by 4 insiders
70% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 14
- Award — granted as compensation
- 17
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Morris Matthew Shawn | — | $11.88M | Jul 6, 2026 |
| Mehrotra Parth | — | $6.43M | May 12, 2026 |
| Mountcastle David | — | $3.72M | Jul 9, 2026 |
| Fargis Edward C | — | $214.8K | Mar 9, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 1, 2026 | Ernest Opella Finley Director | Award | 6,350 | $0 |
| Jul 9, 2026 | Mountcastle David EVP & Chief Financial Officer | Sale 10b5-1 plan | 21,275 | $588.7K |
| Jul 7, 2026 | Mountcastle David EVP & Chief Financial Officer | Sale 10b5-1 plan | 600 | $16.5K |
| Jul 6, 2026 | Morris Matthew Shawn Director | Sale 10b5-1 plan | 53,722 | $1.46M |
| Jul 6, 2026 | Morris Matthew Shawn Director | Option exercise 10b5-1 plan | 53,722 | $107.4K |
| Jul 2, 2026 | Morris Matthew Shawn Director | Sale 10b5-1 plan | 59,037 | $1.61M |
| Jul 2, 2026 | Mountcastle David EVP & Chief Financial Officer | Sale 10b5-1 plan | 24,734 | $680.2K |
| Jul 2, 2026 | Morris Matthew Shawn Director | Option exercise 10b5-1 plan | 59,037 | $118.1K |
| Jul 1, 2026 | Morris Matthew Shawn Director | Sale 10b5-1 plan | 45,634 | $1.21M |
| Jul 1, 2026 | Morris Matthew Shawn Director | Option exercise 10b5-1 plan | 82,675 | $165.3K |
| Jul 1, 2026 | Morris Matthew Shawn Director | Sale 10b5-1 plan | 37,041 | $997.5K |
| Jun 30, 2026 | Morris Matthew Shawn Director | Option exercise 10b5-1 plan | 52,823 | $105.6K |
| Jun 30, 2026 | Morris Matthew Shawn Director | Sale 10b5-1 plan | 52,823 | $1.36M |
| Jun 29, 2026 | Morris Matthew Shawn Director | Sale 10b5-1 plan | 63,212 | $1.60M |
| Jun 29, 2026 | Morris Matthew Shawn Director | Option exercise 10b5-1 plan | 63,212 | $126.4K |
| Jun 26, 2026 | Morris Matthew Shawn Director | Option exercise 10b5-1 plan | 88,110 | $176.2K |
| Jun 26, 2026 | Mountcastle David EVP & Chief Financial Officer | Sale 10b5-1 plan | 17,196 | $433.0K |
| Jun 26, 2026 | Mountcastle David EVP & Chief Financial Officer | Option exercise 10b5-1 plan | 17,196 | $34.4K |
| Jun 26, 2026 | Morris Matthew Shawn Director | Sale 10b5-1 plan | 88,110 | $2.23M |
| May 20, 2026 | KING DAVID P Director | Award | 8,463 | $0 |
| May 20, 2026 | SOISTMAN FRANCIS S JR Director | Award | 8,463 | $0 |
| May 20, 2026 | BERBERIAN LANCE Director | Award | 8,463 | $0 |
| May 20, 2026 | COCOZZA NANCY G Director | Award | 8,463 | $0 |
| May 20, 2026 | Kimmet Pamela O Director | Award | 8,463 | $0 |
| May 20, 2026 | McCarthy Thomas A Director | Award | 8,463 | $0 |
| May 20, 2026 | Morris Matthew Shawn Director | Award | 8,463 | $0 |
| May 20, 2026 | Ryu Jaewon Director | Award | 8,463 | $0 |
| May 12, 2026 | Mehrotra Parth Chief Executive Officer | Sale 10b5-1 plan | 15,647 | $354.2K |
| May 11, 2026 | Mountcastle David EVP & Chief Financial Officer | Sale | 3,385 | $76.5K |
| May 11, 2026 | Mehrotra Parth Chief Executive Officer | Sale 10b5-1 plan | 105,439 | $2.38M |
| May 4, 2026 | Mountcastle David EVP & Chief Financial Officer | Option exercise 10b5-1 plan | 1,206 | $2.4K |
| May 4, 2026 | Mountcastle David EVP & Chief Financial Officer | Sale 10b5-1 plan | 1,206 | $30.1K |
| May 4, 2026 | Morris Matthew Shawn Director | Sale 10b5-1 plan | 1,017 | $25.4K |
| May 4, 2026 | Morris Matthew Shawn Director | Option exercise 10b5-1 plan | 1,017 | $2.0K |
| May 1, 2026 | Mountcastle David EVP & Chief Financial Officer | Option exercise 10b5-1 plan | 7,179 | $14.4K |
| May 1, 2026 | Morris Matthew Shawn Director | Sale 10b5-1 plan | 17,096 | $427.2K |
| May 1, 2026 | Morris Matthew Shawn Director | Option exercise 10b5-1 plan | 17,096 | $34.2K |
| May 1, 2026 | Mountcastle David EVP & Chief Financial Officer | Sale 10b5-1 plan | 7,179 | $179.7K |
| Apr 2, 2026 | Mountcastle David EVP & Chief Financial Officer | Sale | 5,566 | $116.1K |
| Mar 16, 2026 | Mehrotra Parth Chief Executive Officer | Sale | 26,509 | $586.1K |
| Mar 16, 2026 | Mountcastle David EVP & Chief Financial Officer | Sale | 6,391 | $141.3K |
| Mar 13, 2026 | Mountcastle David EVP & Chief Financial Officer | Sale | 6,565 | $141.3K |
| Mar 13, 2026 | Mehrotra Parth Chief Executive Officer | Sale | 27,229 | $586.0K |
| Mar 12, 2026 | Mehrotra Parth Chief Executive Officer | Sale | 26,763 | $586.1K |
| Mar 12, 2026 | Mountcastle David EVP & Chief Financial Officer | Sale | 6,453 | $141.3K |
| Mar 11, 2026 | Mehrotra Parth Chief Executive Officer | Award 10b5-1 plan | 171,904 | $0 |
| Mar 11, 2026 | Mountcastle David EVP & Chief Financial Officer | Award | 42,584 | $0 |
| Mar 10, 2026 | Fargis Edward C EVP & General Counsel | Award | 28,268 | $0 |
| Mar 10, 2026 | Mehrotra Parth Chief Executive Officer | Award 10b5-1 plan | 141,342 | $0 |
| Mar 10, 2026 | Mehrotra Parth Chief Executive Officer | Sale 10b5-1 plan | 21,097 | $479.1K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Privia Health Group, Inc.
Free account. Everything above stays public.
Write why you follow Privia Health Group, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading